Steroid use is on the rise in Australia. Recent figures from the Australian Crime Commission show that the number of steroid-linked arrests and seizures hit a record high in 2011-12. Data from the latest Australian Needle Syringe Program survey showed almost three-quarters of new needle drug users in NSW took image and performance enhancing drugs, predominantly steroids. In November last year, youth workers in Melbourne were reported as saying the number of illegal steroid users obtaining free injecting equipment is increasing, particularly among young men using late-night mobile services.
The Steroid Urine Premium Test can detect a wide variety of illegal substances from the urine samples and makes cheating impossible for the participant. The innovative design of the sample collection device makes it easy to collect as well as allowing you to send the samples through the mail without damage or spilling of the sample ensuring the accuracy of the tests. The huge range of substances that it can detect and the high clarity and readability of the result reports differentiate this test from the multitude of cheaper steroid tests swarming the market today.
On April 8, 1997, after buying the remaining % of Roussel-Uclaf stock in early 1997,  Hoechst AG ( US$30 (equivalent to $ in 2016) billion annual revenue) announced the end of its manufacture and sale of Mifegyne ( US$ (equivalent to $ in 2016) million annual revenue) and the transfer of all rights for medical uses of mifepristone outside of the United States to Exelgyn ., a new single-product company immune to antiabortion boycotts, whose CEO was former Roussel-Uclaf CEO Édouard Sakiz.  In 1999, Exelgyn won approval of Mifegyne in 11 additional countries, and in 28 more countries over the following decade.